5-hydroxymethyl-1,2,3,4-cyclohexanetetrol has been researched along with Diabetes Mellitus, Type 2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hagita, H; Higuchi, T; Ikeda, S; Kato, M; Kobayashi, T; Matsuoka, H; Morikawa, K; Murakata, M; Nishimoto, M; Ohmori, M; Ohtake, Y; Ozawa, K; Sato, T; Shimma, N; Suzuki, M; Taka, N; Takano, K; Yamaguchi, K; Yamamoto, K | 1 |
1 other study(ies) available for 5-hydroxymethyl-1,2,3,4-cyclohexanetetrol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
5a-Carba-β-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Male; Mice; Mice, Obese; Molecular Conformation; Molecular Sequence Data; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution | 2011 |